Bausch + Lomb Posts Q1-2017 Revenues of $1.15 Billion in ‘Solid Quarter’

May 12, 2017: By Joan McKenna

BauschBausch + Lomb posted flat revenues of $1.15 billion on a reported basis (+4 percent in constant currency) in Q1-2017 and provided parent Valeant Pharmaceuticals with a “solid quarter,” company officials announced May 9.

The eye care segment’s revenues accounted for more than half of Valeant’s $2.1 billion in revenues during the quarter.

Bausch + Lomb, based in Bridgewater, New Jersey, saw a 1 percent increase in revenues over Q1-2016’s  $1.146 billion in revenues.

Paul Herendeen, chief financial officer, said Bausch + Lomb’s global ophthalmic pharmaceutical revenues were up 1 percent (+3 cc), with international units offsetting a slight decline in US units.

The global consumer business showed modest revenue growth, while global surgical and vision care declined, he said. Bausch + Lomb completed its acquisition of retinal device maker Synergetics in October 2015 and saw a subsequent boost in surgical sales due to the deal.

Valeant Chief Executive Joseph Papa said Bausch + Lomb’s positive first quarter resulted in part from price increases of about 1.5 percent.

Valeant said Bausch + Lomb’s PreserVision and Ocuvite are the number one ocular vitamin brands globally, while Biotrue is the number one multipurpose solution brand, and PreserVision AREDS 2 Formula (120 count) is the top selling vitamin item in the US.

Bausch + Lomb’s milestones during the quarter include receiving US FDA 510(k) clearances in April for the Stellaris Elite dual cataract/vitrectomy system and Vitesse hypersonic vitrector. The company has FDA target actions dates for Vyzulta (glaucoma) in August 2017 and Luminesse (eye redness) in December 2017.

Growth was primarily driven by increases in volume outside the US, particularly in Europe, the Middle East, South Africa, Asia, and Australia, of $59 million. This was partially offset by declines in US volume of $10 million.

Volume and pricing gains were partially offset by the unfavorable impact of foreign currencies of $41 million and the impact of divestitures and discontinuations of $21 million.

Valeant’s long-term debt now stands at $28.5 billion, with debt reduction continuing to be a priority. Valeant said it has reduced its principal amount of debt by $3.6 billion since Q1-2016.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023